Responses
Regular and young investigator award abstracts
Cellular therapies
145 Preclinical development of EDIT-201, a multiplexed CRISPR-Cas12a gene edited healthy donor derived NK cells demonstrating improved persistence and resistance to the tumor microenvironment
Compose a Response to This Article
Other responses
No responses have been published for this article.
